Interview: Why this biotech chose the ASX over the NASDAQ
FEAR & GREED | Business News · Fear and Greed
October 3, 202211m 54s
Audio is streamed directly from the publisher (p.podderapp.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Imagion Biosystems is a biotech company aiming to make a difference to the lives of cancer patients, with groundbreaking imaging techniques being trialled in Australian hospitals.
CEO Bob Proulx joins Sean Aylmer from San Diego to talk about Imagion's work, and why they chose to list on the ASX.
Find out more: https://fearandgreed.com.au/
See omnystudio.com/listener for privacy information.